


# Inflammation scores based on C-reactive protein and albumin predict mortality in hospitalized older patients independent of the admission diagnosis

## SUPPLEMENTARY MATERIAL

**Figure S1.** Kaplan-Meier survival estimates for (A) Females and (B) Males.



**Table S1.** Hazard ratios for all predictors included in the fully adjusted Cox proportional hazards model.

<b>Model 3</b>	
	<b>HR (95%CI)</b>
<b>CAR</b>	<b>1.94 (1.56-2.41)</b>
<b>Age</b>	<b>1.02 (1.00-1.04)</b>
<b>Female gender, ref. Male</b>	0.88 (0.72-1.06)
<b>5+ Drugs, ref. 0-4</b>	<b>0.69 (0.56-0.85)</b>
<b>3+ lost ADL, ref. 0-2</b>	<b>6.03 (3.79-9.58)</b>
<b>3+ lost IADL, ref. 0-2</b>	0.95 (0.73-1.23)
<b>eGFR (BIS1)</b>	<b>0.99 (0.98-0.99)</b>
<b>NLR</b>	<b>1.02 (1.01-1.02)</b>
<b>ALT</b>	<b>1.0007 (1.0003-1.0010)</b>
<b>Hgb</b>	1.02 (0.97-1.07)
<b>Platelets</b>	0.99 (0.99-1.00)
<b>AMI</b>	1.31 (0.99-1.74)
<b>Cirrhosis</b>	0.76 (0.28-2.04)
<b>CHF</b>	<b>1.90 (1.44-2.50)</b>
<b>Cerebrovascular diseases</b>	0.98 (0.76-1.27)
<b>Dementia</b>	<b>0.77 (0.63-0.95)</b>
<b>COPD</b>	0.90 (0.69-1.16)
<b>Parkinson</b>	1.06 (0.69-1.61)
<b>Hypertension</b>	0.85 (0.70-1.04)
<b>CKD</b>	<b>0.70 (0.56-0.89)</b>
<b>Diabetes</b>	0.99 (0.76-1.30)
<b>Sepsis</b>	<b>1.36 (1.10-1.69)</b>
<b>Cancer</b>	<b>1.67 (1.25-2.22)</b>

In bold significant associations.

**Table S2.** Sex-specific Cox proportional hazards models.

	<b>Females (n=1,863)</b>			<b>Males (n=1,343)</b>		
	<b>Model1</b>	<b>Model2</b>	<b>Model3</b>	<b>Model1</b>	<b>Model2</b>	<b>Model3</b>
	<b>HR (95%CI)</b>	<b>HR (95%CI)</b>	<b>HR (95%CI)</b>	<b>HR (95%CI)</b>	<b>HR (95%CI)</b>	<b>HR (95%CI)</b>
<b>CAR</b>	<b>2.45 (1.91-3.14)</b>	<b>2.39 (1.85-3.08)</b>	<b>1.48 (1.10-2.01)</b>	<b>3.81 (2.82-5.16)</b>	<b>3.73 (2.77-5.03)</b>	<b>2.68 (1.92-3.74)</b>
<b>GPS</b>						
<b>1</b>	<b>1.79 (1.22-2.63)</b>	<b>1.73 (1.18-2.54)</b>	1.38 (0.93-2.06)	<b>2.37 (1.31-4.27)</b>	<b>2.17 (1.20-3.92)</b>	1.43 (0.77-2.63)
<b>2</b>	<b>2.68 (1.83-3.93)</b>	<b>2.47 (1.68-3.64)</b>	<b>1.56 (1.02-2.39)</b>	<b>4.57 (2.56-8.15)</b>	<b>4.22 (2.36-7.54)</b>	<b>2.56 (1.39-4.73)</b>
<b>mGPS</b>						
<b>1</b>	0.80 (0.35-1.81)	0.89 (0.39-2.02)	1.18 (0.52-2.71)	1.23 (0.57-2.66)	1.23 (0.57-2.66)	1.30 (0.57-2.97)
<b>2</b>	<b>1.75 (1.37-2.24)</b>	<b>1.66 (1.30-2.13)</b>	1.21 (0.92-1.60)	<b>2.35 (1.75-3.14)</b>	<b>2.30 (1.72-3.08)</b>	<b>1.92 (1.41-2.61)</b>
<b>hs-mGPS</b>						
<b>1</b>	<b>1.79 (1.06-3.02)</b>	<b>1.76 (1.04-2.97)</b>	1.54 (0.91-2.63)	<b>5.26(1.61-17.19)</b>	<b>5.11(1.56-16.71)</b>	<b>3.62(1.09-12.00)</b>
<b>2</b>	<b>2.96 (1.85-4.75)</b>	<b>2.77 (1.72-4.44)</b>	<b>1.78 (1.09-2.93)</b>	<b>10.31(3.29-32.31)</b>	<b>9.55(3.04-29.98)</b>	<b>5.32(1.66-17.02)</b>

In bold significant associations.

Model 1: unadjusted

Model 2: adjusted for age

Model 3: adjusted for age, 5+ Drugs, 3+ lost ADL, 3+ lost IADL, eGFR, NLR, ALT, Hgb, Platelet, AMI, liver cirrhosis, CHF, CeVD, dementia, COPD, Parkinson, hypertension, CKD, diabetes, sepsis, cancer